Othman, Jad, Wilhelm-Benartzi, Charlotte S. ORCID: https://orcid.org/0000-0003-4927-6158, Dillon, Richard, Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441, Freeman, Sylvie D., Batten, Leona M., Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Hinson, Emily L., Wych, Julie, Betteridge, Sophie, Villiers, William, Kleeman, Michelle, Gilkes, Amanda Frances, Potter, Nicola, Overgaard, Ulrik, Mehta, Priyanka, Kottaridis, Panagiotis, Cavenagh, Jamie, Hemmaway, Claire Jane, Arnold, Claire, Dennis, Mike and Russell, Nigel H. 2023. A randomised comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial. Blood Advances 7 (16) , pp. 4539-4549. 10.1182/bloodadvances.2023010276 |
Russell, Nigel H., Wilhelm-Benartzi, Charlotte ORCID: https://orcid.org/0000-0003-4927-6158, Knapper, Steve ORCID: https://orcid.org/0000-0002-6405-4441, Batten, Leona M., Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Hinson, Emily L., Overgaard, Ulrik Malthe, Gilkes, Amanda, Othman, Jad, Potter, Nicola, Dillon, Richard, Mehta, Priyanka, Kottaridis, Panagiotis, Cavenagh, Jamie, Hemmaway, Claire, Arnold, Claire, Freeman, Sylvie D and Dennis, Mike 2022. FLAG-Ida combined with Gemtuzumab Ozogamicin (GO) improves event free survival in younger patients with newly diagnosed Acute Myeloid Leukaemia (AML) and shows an overall survival benefit in NPM1 and FLT3 mutated subgroups. Results from the UK NCRI AML19 trial. Blood 140 (S1) , pp. 526-528. 10.1182/blood-2022-162377 |
Othman, Jad, Dillon, Richard, Wilhelm-Benartzi, Charlotte ORCID: https://orcid.org/0000-0003-4927-6158, Knapper, Steve ORCID: https://orcid.org/0000-0002-6405-4441, Batten, Leona M, Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Hinson, Emily L., Villiers, William, Kleeman, Michelle, Gilkes, Amanda, Potter, Nicola, Overgaard, Ulrik Malthe, Mehta, Priyanka, Kottaridis, Panos, Cavenagh, Jamie, Hemmaway, Claire, Arnold, Claire, Dennis, Mike and Russell, Nigel H. 2022. Genomic correlates of outcome in a randomised comparison of CPX-351 and FLAG-Ida in high-risk acute myeloid leukaemia and myelodysplastic syndrome: results from the UK NCRI AML19 Trial. Presented at: 64th ASH Annual Meeting and Exposition, New Orleans, Louisiana, 10-13 December 2022. Blood. , vol.140 (S1) American Society of Hematology, pp. 1036-1038. 10.1182/blood-2022-159433 |
Mukherjee, Somnath, Hurt, Christopher ORCID: https://orcid.org/0000-0003-1206-8355, Radhakrishna, Ganesh, Gwynne, Sarah, Bateman, Andrew, Gollins, Simon, Hawkins, Maria A., Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Grabsch, Heike I., Falk, Stephen, Sharma, Ricky A., Ray, Ruby, Roy, Rajarshi, Cox, Catrin, Maynard, Nick, Nixon, Lisette ORCID: https://orcid.org/0000-0002-1270-6970, Sebag-Montefiore, David J., Maughan, Timothy, Griffiths, Gareth O. and Crosby, Tom D.L. 2021. Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. European Journal of Cancer 153 , pp. 153-161. 10.1016/j.ejca.2021.05.020 |
Mukherjee, Somnath, Hurt, Christopher Nicholas ORCID: https://orcid.org/0000-0003-1206-8355, Gwynne, Sarah, Sebag-Montefiore, David, Radhakrishna, Ganesh, Gollins, Simon, Hawkins, Maria, Grabsch, Heike I., Jones, Gareth, Falk, Stephen, Sharma, Ricky, Bateman, Andrew, Roy, Rajarshi, Ray, Ruby, Canham, Jo ORCID: https://orcid.org/0000-0003-3482-0990, Griffiths, Gareth, Maughan, Tim and Crosby, Tom 2017. NEOSCOPE: a randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. European Journal of Cancer 74 , pp. 38-46. 10.1016/j.ejca.2016.11.031 |
Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990
2016.
The development of an intervention to support job retention and return to work for individuals with a diagnosis of bipolar disorder.
PhD Thesis,
Cardiff University.
Item availability restricted. |
Mukherjee, Somnath, Hurt, Chris Nicholas ORCID: https://orcid.org/0000-0003-1206-8355, Gwynne, Sarah, Bateman, Andrew, Gollins, Simon, Radhakrishna, Ganesh, Hawkins, Maria, Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Lewis, Wyn, Grabsch, Heike I, Sharma, Ricky A, Wade, Wendy, Maggs, Rhydian, Tranter, Bethan, Roberts, Ashley, Sebag-Montefiore, David, Maughan, Timothy, Griffiths, Gareth and Crosby, Tom 2015. NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. BMC Cancer 15 (1) , 48. 10.1186/s12885-015-1062-y |
Cohen, Deborah, Rees, Sarah, Palmer, Paula, Allen, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Howells, Sophie, Greene, Giles ORCID: https://orcid.org/0000-0001-9326-8740 and Rhydderch, Melody 2013. Factors that impact on medical student wellbeing: perspectives of risks. [Project Report]. Gneral Medical Council. Available at: https://www.gmc-uk.org/about/what-we-do-and-why/da... |
Cohen, Deborah Anne, Khan, S., Allen, Joanna ORCID: https://orcid.org/0000-0003-3482-0990 and Sparrow, N. 2012. Shifting attitudes: the National Education Programme for work and health. Occupational Medicine 62 (5) , pp. 371-374. 10.1093/occmed/kqs081 |
Cohen, Deborah Anne, Allen, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Rhydderch, Sara Melody and Aylward, Mansel 2012. The return to work discussion: A qualitative study of the line manager conversation about return to work and the development of an educational programme. Journal of Rehabilitation Medicine 44 (8) , pp. 677-683. 10.2340/16501977-0996 |